Formulation Optimization of Serratiopeptidase-loaded PLGA Microspheres Using Selected Variables

References

1. 1.↵
   1. Hunt T. K.,
   2. Hopf H.,
   3. Hussain Z.,

   Physiology of wound healing. Adv. Skin Wound Care 2000, 13 ( 2 Suppl.), 6– 11.

   OpenUrlPubMed
2. 2.↵
   1. Burke J. F.,

   The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961, 50 ( July), 161– 168.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. Yaakobi T.,
   2. Roth D.,
   3. Chen Y.,
   4. Freeman A.,

   Streaming of proteolytic enzyme solutions for wound debridement: a feasibility study. Wounds 2004, 16 ( 6), 201– 205.

   OpenUrl
4. 4.↵
   1. Jenning V.,
   2. Schafer-Korting M.,
   3. Gohla S.,

   Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Controlled Release 2000, 66 ( 2–3), 115– 126.

   OpenUrlPubMed
5. 5.↵
   1. Kee W. H.,
   2. Tan S. L.,
   3. Lee V.,
   4. Salmon Y. M.,

   The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med. J 1989, 30 ( 1), 48– 54.

   OpenUrlPubMed
6. 6.↵
   1. Majima Y.,
   2. Hirata K.,
   3. Takeuchi K.,
   4. Hattori M.,
   5. Sakakura Y.,

   Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respir. Dis 1990, 141 ( 1), 79– 83.

   OpenUrlPubMedWeb of Science
7. 7.↵
   1. Rawat M.,
   2. Singh D.,
   3. Saraf S.,
   4. Saraf S.,

   Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull 2006, 29 ( 9), 1790– 1798.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Gombotz W. R.,
   2. Pettit D. K.,

   Biodegradable polymers for protein and peptide drug delivery. Bioconjug. Chem 1995, 6 ( 4), 332– 351.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Schwendeman S. P.,
   2. Cardamone M.,
   3. Brandon M. R.,
   4. Klibanov A.,
   5. Langer R.,

   Stability of Proteins and Their Delivery from Biodegradable Polymer Microparticles. In Microparticulate Systems for the Delivery of Proteins and Vaccines; Marcel Dekker: New York, 1996; pp 1– 49.
10. 10.↵
    1. Rössler B.,
    2. Kreuter J.,
    3. Ross G.,

    Effect of collagen microparticles on the stability of retinol and its adsorption into hairless mouse skin in vitro. Pharmazie 1994, 49 ( 2–3), 175– 179.

    OpenUrlPubMed
11. 11.↵
    1. Brosse C.,
    2. Soutif J. C.,
    3. Bross J. C.,

    Preparation of microcapsules for skin allergy testing by solvent evaporation process. J. Microencapsul 2000, 17 ( 1), 111– 116.

    OpenUrlPubMed
12. 12.↵
    1. Ogawa Y.,
    2. Yamamoto M.,
    3. Okada H.,
    4. Yashiki T.,
    5. Shimamoto T.,

    A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull. (Tokyo) 1988, 36 ( 3), 1095– 1103.

    OpenUrlPubMed
13. 13.↵
    1. Wise D. L.,

    1. Brannon-Peppas L.,
    2. Vert M.,

    Polylactic and Polyglycolic Acid Acids as Drug Carriers. In Handbook of Pharmaceutical Controlled Release Technology; Wise D. L., Ed.; Marcel Dekker: New York, 2000; pp 99– 130.
14. 14.↵
    1. Rawat M.,
    2. Singh D.,
    3. Saraf S.,
    4. Saraf S.,

    Development and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzyme. Drug Dev. Ind. Pharm 2008, 34 ( 2), 181– 188.

    OpenUrlPubMed
15. 15.↵
    1. Rawat M.,
    2. Saraf S.,
    3. Saraf S.,

    Influence of selected formulation variables on the preparation of enzyme entrapped Eudragit S100 microspheres. AAPS PharmSciTech 2007, 8 ( 4), E116.

    OpenUrlPubMed
16. 16.↵
    1. Bolton S.,

    Pharmaceutical Statistics: Practical and Clinical Applications, 2nd ed.; Marcel Dekker: New York, 1990.
17. 17.↵
    1. Bloomfield M. S.,
    2. Butler W. C.,

    Robustness testing, using experimental design, of a flow-through dissolution method for a product where actives have markedly differing solubility properties. Int. J. Pharm 2000, 206 ( 1–2), 55– 61.

    OpenUrlPubMed
18. 18.↵
    1. Cohen S.,
    2. Yoshiaka T.,
    3. Lucarelli M.,
    4. Hwang L. H.,
    5. Langer R.,

    Controlled delivery system for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res 1991, 8 ( 6), 713– 720.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Jain D.,
    2. Panda A. K.,
    3. Majumdar D. K.,

    Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS PharmSciTech 2005, 6 ( 1), E100– E107.

    OpenUrlPubMed
20. 20.↵
    1. Rosa G. D.,
    2. Iommelli R.,
    3. La Rotonda M. I.,
    4. Miro A.,
    5. Quaglia F.,

    Influence of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J. Controlled Release 2000, 69, 283– 295.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Lee J. H.,
    2. Park T. G.,
    3. Lee Y. B.,
    4. Shin S. C.,
    5. Choi H. K.,

    Effect of adding non-volatile oil as a core material for the floating microspheres prepared by emulsion solvent diffusion method. J. Microencapsul 2001, 18 ( 1), 65– 75.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Dashora K.,
    2. Saraf S.,
    3. Saraf S.,

    Effect of processing variables on micro particulate system of aceclofenac. Pak. J. Pharm. Sci 2006, 19 ( 1), 6– 10.

    OpenUrlPubMed
23. 23.↵
    1. Saudagar R. B.,
    2. Rawat M.,
    3. Singh D.,
    4. Saraf S.,
    5. Saraf S.,

    Development and validation of derivative spectrophotometric method for determination of serratiopeptidase in pharmaceutical formulation. Oriental J. Chem. 2008, 23, 113– 114.

    OpenUrl
24. 24.↵
    Committee on Institute of Medicinez. Food and Chemical Codex, 4th ed. Washington, DC; National Academic Press, 2003.
25. 25.↵
    1. Uchida T.,
    2. Yoshida K.,
    3. Ninomiya A.,
    4. Goto S.,

    Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin. Chem. Pharm. Bull. (Tokyo) 1995, 43 ( 9), 1569– 1573.

    OpenUrlPubMed
26. 26.↵
    1. Jalil R.,
    2. Nixon J. R.,

    Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J. Microencapsul 1990, 7 ( 3), 297– 325.

    OpenUrlPubMedWeb of Science
27. 27.↵
    1. Salamone P. R.,
    2. Wodzinski R. J.,

    Production, purification and characterization of a 50-kDa extracellular metalloprotease from Serratia marcescens. Appl. Microbiol. Biotechnol. 1997, 48 ( 3), 317– 324.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Mendenhall W.,
    2. Sincich T.,

    Multiple Regression: A Second Course in Business Statistics: Regression Analysis, 3rd ed.; Dellen Publishing: CA, 1989.
29. 29.↵
    1. Martinez-Sancho C.,
    2. Herrero-Vanrell R.,
    3. Negro S.,

    Optimisation of aciclovir poly(D,L-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study. Int. J. Pharm 2004, 273 ( 1–2), 45– 56.

    OpenUrlPubMed
30. 30.↵
    1. Cheu S. J.,
    2. Chen R. R.,
    3. Chen P. F.,
    4. Lin W. J.,

    In vitro modified release of acyclovir from ethyl cellulose microspheres. J. Microencapsul 2001, 18 ( 5), 559– (2001).

    OpenUrlPubMed
31. 31.↵
    1. Lin Y. H.,
    2. Vasavada R. C.,

    Studies on microencapsulation of 5-fluorouracil with poly(ortho ester) polymers. J. Microencapsul 2000, 17 ( 1), 1– 11.

    OpenUrlPubMed
32. 32.↵
    1. Onuki Y.,
    2. Morishita M.,
    3. Takayama K.,

    Formulation optimization of water-in-oil-water multiple emulsion for intestinal insulin delivery. J. Controlled Release 2004, 97 ( 1), 91– 99.

    OpenUrlPubMed
33. 33.↵
    1. Vyas S. P.,
    2. Rawat M.,
    3. Rawat A.,
    4. Mahor S.,
    5. Gupta P. N.,

    Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of Interferon-α. Drug Dev. Ind. Pharm 2006, 32 ( 6), 699– 707.

    OpenUrlPubMed
34. 34.↵
    1. Tzafiriri A. R.,

    Mathematical modeling of diffusion-mediated release from bulk degrading matrices. J. Controlled Release 2000, 63 ( 1–2), 69– 79.

    OpenUrlCrossRefPubMed